Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · Journal of Clinical Oncology · 2011 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +15

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David Miles, Arlene Chan, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 887 citations

Medicine, Oncology, Pharmacology +17

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Bryan P. Schneider, Milan Radovich, George W. Sledge et al. · Journal of Clinical Oncology · 2008 · 608 citations · Full text

Medicine, Oncology, Pharmacology +17

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Robert J. Gray, Suman Bhattacharya, Christopher Bowden et al. · Journal of Clinical Oncology · 2009 · 294 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · Journal of Clinical Oncology · 2010 · 186 citations

Medicine, Oncology, Pharmacology +12